Sandoz, Teva And Mylan Step Up On Hydroxychloroquine
As White House And FDA Ramp Up Coronavirus Research
To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.
You may also be interested in...
As one of the largest players in the industry, Sandoz has undertaken several key measures to aid in the fight against the novel coronavirus outbreak, including maintaining stable prices for key measures and donating millions of doses of potential treatment options like hydroxychloroquine. CEO Richard Saynor sets out his thoughts on the ongoing pandemic and the role of the generics industry.
Amid media reports of Teva walking away from settlement negotiations with the US Department of Justice over generic price-fixing allegations, the Israeli company is officially maintaining silence over the matter.
A drug safety communication published by the US FDA over hydroxychloroquine and chloroquine has cooled hopes that the drugs could be used as key treatments to address the coronavirus pandemic.